Fischer Medical Ventures Ltd (IN:FISCHER)
:FISCHER
Want to see IN:FISCHER full AI Analyst Report?
Top Page
Fischer Medical Ventures Ltd
(FISCHER)
Select Model
Select Model
Rating:47Neutral
Price Target:
₹37.00
▼(-15.27% Downside)
Action:Upgraded
Date:12/18/25
Fischer Medical Ventures Ltd faces significant challenges with profitability and cash flow, reflected in a low financial performance score. The technical analysis indicates bearish momentum, and the high P/E ratio suggests overvaluation. These factors contribute to a lower overall stock score.
Positive Factors
Revenue Growth
Sustained revenue growth indicates the company is expanding its market traction and demand for its medical-device offerings. Over a 2–6 month horizon this supports scalability and revenue visibility, providing a base to improve margins if cost structure is addressed.
Negative Factors
Negative Operating & Free Cash Flow
Persistent negative operating and free cash flows indicate the business is not converting profits into cash, constraining internal funding for capex, R&D, or working capital. Even with low leverage, continued cash burn forces reliance on external financing and weakens long-term resilience.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained revenue growth indicates the company is expanding its market traction and demand for its medical-device offerings. Over a 2–6 month horizon this supports scalability and revenue visibility, providing a base to improve margins if cost structure is addressed.
Read all positive factors
Fischer Medical Ventures Ltd (FISCHER) vs. iShares MSCI India ETF (INDA)
Market Cap
₹22.72B
Dividend Yield0.01%
Average Volume (3M)267.56K
Price to Earnings (P/E)35.3
Beta (1Y)0.32
Revenue Growth215.87%
EPS Growth758.60%
CountryIN
Employees40
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.22
Shares Outstanding648,515,440
10 Day Avg. Volume611,655
30 Day Avg. Volume267,556
Financial Highlights & Ratios
PEG Ratio-97.87
Price to Book (P/B)33.38
Price to Sales (P/S)101.77
P/FCF Ratio-121.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Fischer Medical Ventures Ltd Business Overview & Revenue Model
Company Description
Fischer Medical Ventures Limited engages in the manufacture, distribution, leasing, and maintenance of medical equipment in India and internationally. Its product portfolio includes magnetic resonance imaging (MRI) systems; preventive health kiosk...
Fischer Medical Ventures Ltd Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
70
Positive
Cash Flow
40
Negative
| Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.35B | 1.11B | 209.81M | 1.79M | 0.00 |
| Gross Profit | 302.73M | 191.09M | 45.27M | 1.79M | 0.00 |
| EBITDA | 212.21M | 42.58M | 23.61M | 152.00K | -1.89M |
| Net Income | 152.08M | 12.08M | 18.38M | -365.00K | -2.33M |
Balance Sheet | |||||
| Total Assets | 4.68B | 4.57B | 863.22M | 3.54M | 1.90M |
| Cash, Cash Equivalents and Short-Term Investments | 428.70M | 2.51B | 379.46M | 358.00K | 156.00K |
| Total Debt | 370.08M | 853.72M | 16.77M | 11.43M | 3.89M |
| Total Liabilities | 1.07B | 1.20B | 52.07M | 6.20M | 4.20M |
| Stockholders Equity | 3.60B | 3.38B | 811.14M | -2.66M | -2.29M |
Cash Flow | |||||
| Free Cash Flow | -1.49B | -927.25M | -78.37M | -1.46M | -1.77M |
| Operating Cash Flow | -1.36B | -867.38M | -73.52M | -1.46M | -1.77M |
| Investing Cash Flow | -2.44B | -1.25B | -313.86M | 0.00 | 0.00 |
| Financing Cash Flow | 2.75B | 3.15B | 370.57M | 1.66M | 1.48M |
Fischer Medical Ventures Ltd Technical Analysis
Negative
43.67
Price Trends
37.52
Negative
38.70
Negative
63.44
Negative
Market Momentum
-1.07
Positive
36.63
Neutral
31.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:FISCHER, the sentiment is Negative. The current price of 43.67 is above the 20-day moving average (MA) of 36.76, above the 50-day MA of 37.52, and below the 200-day MA of 63.44, indicating a bearish trend. The MACD of -1.07 indicates Positive momentum. The RSI at 36.63 is Neutral, neither overbought nor oversold. The STOCH value of 31.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:FISCHER.
Fischer Medical Ventures Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹105.27B | 15.54 | ― | 0.41% | 4.88% | 66.43% | |
73 Outperform | ₹75.51B | 34.04 | ― | 0.68% | 20.61% | 78.25% | |
71 Outperform | ₹98.40B | 18.03 | ― | 0.44% | 13.29% | -2.17% | |
59 Neutral | ₹63.53B | 35.56 | ― | 0.67% | -12.47% | -14.29% | |
54 Neutral | ₹93.31B | 35.22 | ― | 0.16% | 14.80% | 63.75% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ₹22.72B | 35.32 | ― | 0.01% | 215.87% | 758.60% |
* Healthcare Sector Average
IN:FISCHER
Fischer Medical Ventures Ltd
34.92
-47.12
-57.44%
IN:AARTIPHARM
Aarti Pharmalabs Limited
703.50
-165.30
-19.03%
IN:MARKSANS
Marksans Pharma Limited
216.05
-29.78
-12.11%
IN:SHILPAMED
Shilpa Medicare Limited
475.15
108.09
29.45%
IN:STAR
Strides Pharma Science Ltd
1,158.90
431.83
59.39%
IN:THYROCARE
Thyrocare Technologies Ltd
469.70
154.54
49.04%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.